Ubiquitin ligase RNF8 suppresses Notch signaling to regulate mammary development and tumorigenesis by Li, Li et al.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
4 5 2 5jci.org   Volume 128   Number 10   October 2018
Introduction
Regulation of Notch signaling and repair of double-strand breaks 
(DSBs) is critical for maintaining tissue homeostasis and suppres-
sion of cancer. Notch signaling is important for the control of cell-
fate determination of mammary epithelial cell (MEC) progenitors, 
and its abnormal activation is associated with human and mouse 
breast tumorigenesis (1–3). Defective DSB signaling promotes 
genomic instability and increases the risk for various human neo-
plasms, including breast cancer (4).
Notch signaling and DSB repair are highly regulated by post-
translational modifications including ubiquitylation (2, 5, 6). The 
E3 ligase RNF8 ubiquitylates histone H1 at DSB flanking sites, 
triggering an orchestrated recruitment of signaling and repair 
proteins (e.g., the breast cancer susceptibility protein BRCA1) to 
facilitate the repair of the break sites (7–13). Despite impaired DSB 
repair signaling in the absence of RNF8, and the reported RNF8 
function in the activation of TWIST and cancer metastasis (14), 
whether deficiency of RNF8 promotes breast cancer initiation and 
development has yet to be examined. Here, we aimed to address 
the effect of Rnf8 mutation on mammary tumorigenesis. Notably, 
we also uncovered novel functions of RNF8 in the regulation of 
Notch signaling and cell-fate determination of MECs. Given the 
importance of DSB repair and Notch signaling in breast cancer, 
identification of mechanisms that coregulate these pathways will 
not only reveal novel key cancer drivers, but also can potentially 
provide novel, more effective, and precise therapeutic strategies.
Results
RNF8 deficiency promotes mouse mammary tumorigenesis. To exam-
ine whether RNF8 deficiency fosters mammary tumorigenesis, 
we first examined mammary tissues of Rnf8–/– female mice. While 
Rnf8–/– females frequently developed hyperplastic lesions in mam-
mary tissues at 13 months of age (60%; 12 of 20), no hyperplasia 
was observed in WT littermates (n = 19; Supplemental Figure 1, 
A and B; supplemental material available online with this article; 
https://doi.org/10.1172/JCI120401DS1). Next, monitoring the 
cohorts of Rnf8–/– females and WT controls for over 600 days, we 
observed that in addition to thymomas and/or lymphomas, 18% of 
Rnf8–/– females (6 of 33) also developed mammary adenocarcino-
mas (Figure 1, A and B).
Human TP53, and its mouse ortholog TRP53, are tumor sup-
pressors important for the DNA damage response (DDR) (15, 16). 
Examination of Rnf8–/– mammary glands indicated upregulated 
expression of TRP53 and its transcriptional targets P21 and BAX, 
suggesting abnormally activated DDR in the absence of RNF8 
(Supplemental Figure 1C). Based on the frequent mutations of 
TP53 in human breast cancer (17), we sought to examine the effect 
of inactivation of TRP53 in mammary tumorigenesis associated 
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In contrast, the other RNF8 isoforms (201, 204, and 208) lack the 
FHA domain, the RING-finger domain, or both and therefore are 
predicted to be nonfunctional (Figure 2A). KM Plotter analysis of 
breast cancer patients was performed using the median expression 
level as the cutoff. Since the 203160_s_at probe set recognizes RNF8 
transcripts lacking functional domains (Figure 2A), these analyses 
indicated a modest association between high RNF8 expression and 
reduced relapse-free survival of breast cancer patients (Supplemen-
tal Figure 2A; hazard ratio = 1.15 [1.03–1.28], log-rank P = 0.013). 
However, the same analysis using the functionally relevant RNF8 
probe set (203161_s_at), specific to the full transcript encoding the 
functional RNF8, revealed that low RNF8 expression significantly 
associates with poorer outcome (Figure 2B; hazard ratio = 0.82 
[0.74–0.92], log-rank P = 4 × 10–04). The strongest associations using 
RNF8 203161_s_at were observed for luminal B and basal-like breast 
cancer subtypes (Figure 2, C and D). The HER2+ subtype showed an 
effect in the same direction, although with lower significance due to 
the substantially smaller sample size in this setting (Figure 2E).
RNF8 deficiency promotes genomic instability in MECs and 
tumors. Given the established role of genomic instability in driv-
ing cancer (23), we examined the effect of RNF8 deficiency 
on DSB signaling, repair, and genomic integrity in MECs. 
Examination of γH2AX foci, a marker for DSBs (24), indicated 
elevated levels of spontaneous and γ-irradiation–induced (IR- 
induced) DSBs in Rnf8–/– MECs compared with WT controls (Fig-
ure 3, A and B). We also examined DSB levels in Rnf8–/– Trp53Δ/Δ 
mam mary tumor cell lines reconstituted with mock or RNF8WT. 
We observed that RNF8WT‑reconstituted Rnf8–/– Trp53Δ/Δ mammary 
tumor cells displayed significantly lower levels of spontaneous DSBs, 
and their resolution of IR-induced DSBs was more efficient, com-
pared with their mock-reconstituted controls (Figure 3, C–E). Recon-
stitution of Rnf8–/– Trp53Δ/Δ mammary tumor cells with RNF8WT 
also restored the ability of these tumor cells to recruit homologous 
recombination (HR) and nonhomologous end joining (NHEJ) repair 
factors BRCA1, RAD51, and 53BP1 to DSB sites (Figure 3, D–F). Con-
sistent with these data, complementation of RNF8-deficient tumor 
cells with RNF8 significantly increased their efficiency of HR- and 
NHEJ-mediated DSB repair (Figure 3, G and H). Collectively these 
data underscore the importance of RNF8 for maintaining genomic 
stability in mammary cancer cells and tumors.
Aberrant expansion of the mammary luminal progenitors in the 
absence of RNF8. Deregulated lineage commitment of MECs has 
been shown to be associated with increased breast cancer risk (1, 
25). Therefore, we also investigated the role of RNF8 in mammary 
gland development and its link to tumorigenesis. First, analysis of 
Rnf8 expression in mammary cell subpopulations indicated a sig-
nificantly lower level in luminal progenitors compared with lumi-
nal differentiated and basal cells (Supplemental Figure 3A). Next, 
mammary epithelial subpopulations of 10- to 12-week-old, tumor-
free, Rnf8–/– females and WT littermates were examined for poten-
tial differences. Notably, studied females were in estrus to alleviate 
hormonal effects on homeostasis of MECs (26, 27). Flow cytom-
etry analyses indicated aberrant expansion of the luminal lineage 
in Rnf8–/– females compared with WT littermates (Figure 4, A–C; 
Lin– luminal cells: P < 0.05, 36.2% ± 1.8% vs. 20.5% ± 0.4%; Lin– 
basal cells: P > 0.05, 9.3% ± 1.2% vs. 13% ± 0.3%). In addition, there 
was an expansion of the luminal progenitor subpopulation (CD29lo 
with Rnf8 mutation. Mice constitutively lacking RNF8 and TRP53 
(Rnf8–/– Trp53–/–) died by approximately 12 weeks of age due to 
thymomas (18), precluding the examination of their risk for mam-
mary tumorigenesis. To circumvent this limitation, Rnf8–/– and 
WapCre Trp53fl/fl mice were crossed to generate Rnf8–/– females 
in which Trp53 is conditionally deleted in the mammary epithe-
lium following pregnancy. Monitoring cohorts of Rnf8–/– WapCre 
Trp53fl/fl, WapCre Trp53fl/fl, Rnf8–/–, and WT females, we observed 
that Trp53 deletion in the MECs of Rnf8–/– females significantly 
accelerated the incidence of mammary adenocarcinomas (Figure 
1, A and B, and Supplemental Figure 1D). Interestingly, Rnf8–/– 
females lacking 1 copy of Trp53 in their MECs (Rnf8–/– WapCre 
Trp53fl/WT) also displayed elevated risk for developing mammary 
tumors, and these malignant lesions showed loss of heterozygosity 
for Trp53 (Figure 1A and Supplemental Figure 1E).
Mammary tumors developed by Rnf8–/–, Rnf8–/– WapCre 
Trp53fl/fl (referred to as Rnf8–/– Trp53Δ/Δ), and WapCre Trp53fl/fl 
(Trp53Δ/Δ) females exhibited predominant positivity for the lumi-
nal marker cytokeratin 18 (CK18) (Figure 1B). Rnf8–/– Trp53Δ/Δ 
mammary tumors were also positive for estrogen receptor (ER) 
(Supplemental Figure 1F), and exhibited metastasis to other 
organs (e.g., lung, lymph nodes, and brain) as confirmed by 
pan-CK staining (Supplemental Figure 1F). Moreover, Rnf8–/–, 
Rnf8–/– Trp53Δ/Δ, Rnf8–/– Trp53Δ/WT, and Trp53Δ/Δ mammary tumors 
were Lin– (lineage-negative: CD45–CD31–TER119–) and enriched 
for CD49floCD24+CD61+, markers of luminal progenitor 
subpopulation (Supplemental Figure 1G).
Next, we sought to examine the effect of complementation 
of Rnf8‑deficient mammary tumor cells with Rnf8WT on their in 
vivo growth capacity. We observed that relative to empty-vector 
controls, RNF8-reconstituted Rnf8–/– Trp53Δ/Δ tumor cells showed 
reduced growth when engrafted in inguinal fat pads of NOD scid 
gamma (NSG) mice as measured by tumor volume and mass (Fig-
ure 1, C–E, and Supplemental Figure 1H). Examination of the corre-
sponding tumors revealed that RNF8WT reconstitution significantly 
restrained cancer cell proliferation as assessed with Ki67 staining 
(Supplemental Figure 1, I and J). Collectively, these data highlight 
the importance of RNF8 expression, and its collaboration with 
TRP53 function, in suppressing mammary tumorigenesis.
Low expression of the full‑length RNF8 correlates with poor progno‑
sis of breast cancer patients. To examine the clinical relevance of RNF8 
expression levels in human breast cancer subtypes, we used the 
Kaplan-Meier Plotter (KM Plotter) tool to analyze an integrated data 
set including 5,143 breast cancer cases of which 3,955 had relapse-
free survival information (19). Two Affymetrix microarray probes for 
RNF8 are included in the application (Figure 2A). Disparity of results 
between microarray probes supposedly mapping on a single gene 
target has been previously recognized (e.g., BRCA1 and MYC) (20–
22). Therefore, we first examined curated Ensembl annotations and 
observed that the human RNF8 locus includes at least 4 isoforms 
(Figure 2A). Examination of the 2 Affymetrix microarray probes for 
RNF8 indicated that they display different specificity toward these 
isoforms. While 203160_s_at recognizes all 4 isoforms, 203161_s_at 
only recognizes the transcript (RNF8-202) that encodes for the 
complete functional protein (according to UniProt, O76064_1), 
including its forkhead-associated (FHA) and RING-finger domains 
(Figure 2A), both required for RNF8 function in DSB repair (7–10). 
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Figure 1. RNF8 deficiency promotes 
spontaneous mammary tumorigene-
sis in mouse models. (A) Kaplan-Meier 
mammary tumor-free survival curves 
of cohorts of WT (n = 23), Rnf8–/– (n = 
33), WapCre Trp53fl/fl (n = 28), WapCre 
Trp53fl/WT (n = 12), Rnf8–/– WapCre 
Trp53fl/WT (n = 16), and Rnf8–/– WapCre 
Trp53fl/fl (n = 31) females. Log-rank 
tests indicate statistically significant 
differences between Rnf8–/– and WT 
curves (P = 0.005), Rnf8–/– and Rnf8–/– 
WapCre Trp53fl/fl curves (P < 0.0001), 
Rnf8–/– WapCre Trp53fl/fl and WapCre 
Trp53fl/fl curves (P < 0.0001), and 
Rnf8–/– WapCre Trp53fl/WT and WapCre 
Trp53fl/WT curves (P < 0.003). (B) 
Representative H&E and cytokeratin 
(CK18 and CK14) immunohistochemical 
staining of Rnf8–/–, WapCre Trp53fl/fl 
(Trp53Δ/Δ), and Rnf8–/– WapCre Trp53fl/fl 
(Rnf8–/– Trp53Δ/Δ) mammary adeno-
carcinomas. At least 3 tumors per 
genotype were examined. Scale bars: 
50 μm. (C) Representative photo-
graphs of Rnf8–/– Trp53Δ/Δ mammary 
tumors, either mock- or RNF8-recon-
stituted (as indicated), 40 days after 
orthotopic injection of these tumor 
cells into inguinal fat pads of NSG mice 
(n = 10–12 each). (D) Dot plots showing 
volume of tumors (n = 10–12 each; 
mean ± SEM) monitored for 40 days 
using external caliper. ***P < 0.001, 
2-way ANOVA followed by Tukey’s 
test. (E) Dot plots depict average mass 
(mean ± SEM) of tumors resected from 
NSG mice (n = 10–12) following 40 days 
of outgrowth. ***P < 0.001, 2-sided 
Student’s t test.
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Figure 2. Low expression of the full-length RNF8 correlates with poor prognosis for breast cancer patients. (A) Schematic of the different human RNF8 isoforms 
and the position of the 2 Affymetrix microarray probes 203160_s_at and 203161_s_at included in the KM Plotter application. The 203160_s_at probe recognizes all 
4 RNF8 isoforms; the 203161_s_at probe only recognizes the full-length transcript (RNF8-202) that encodes for the full-length functional RNF8 protein containing 
both its FHA and its RING-finger domains. (B–E) Analysis of relapse-free survival of breast cancer patients using KM Plotter and the median expression level of 
the RNF8 203161_s_at probe to classify breast cancer cases as expressing either high or low levels of the full-length isoform. The analysis included all breast cancer 
patients (n = 3,955) and patients with luminal B (n = 1,149), basal-like (n = 618), or HER2+ (n = 251) subtypes. Hazard ratio and 95% confidence intervals of the Cox 
regression analysis and log-rank P values are shown. NMD, nonsense-mediated decay.
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these data support increased NOTCH transcriptional activity in 
Rnf8–/– mammary luminal progenitors, thus providing a possible 
mechanism for their aberrant expansion.
Given that gain-of-function mutations of NOTCH1 are associated 
with human breast cancer (2, 3), and that Notch signaling is activated 
in Rnf8–/– luminal progenitors, we examined the level of this signaling 
in Rnf8–/– Trp53Δ/Δ mammary tumors. Immunohistochemical stain-
ing indicated increased expression of N1ICD in Rnf8–/– and Rnf8–/– 
Trp53Δ/Δ primary mammary tumors relative to Trp53Δ/Δ tumors (Figure 
5C). Consistent with these data, Rnf8–/– Trp53Δ/Δ mammary tumor 
cells displayed elevated expression of N1ICD and its targets (HES1 
and CCND1), and the activation of Notch1 signaling was restrained 
following RNF8WT reconstitution (Figure 5D and Supplemental Figure 
1H). In addition, expression of NOTCH targets was higher in mock- 
reconstituted Rnf8–/– Trp53Δ/Δ mammary tumor cells engrafted into 
NSG mice, compared with the corresponding RNF8WT-reconstituted 
controls (Figure 5E). Moreover, a reporter for Notch signaling activity 
(10xCBF1-Luc) (33) confirmed RNF8-mediated negative regulation 
of NOTCH transcriptional activity in RNF8WT-reconstituted Rnf8–/– 
Trp53Δ/Δ cells (Figure 5F).
To further investigate the functional relevance of RNF8 to 
the regulation of Notch signaling, we compared RNA sequenc-
ing data obtained from Rnf8–/– Trp53Δ/Δ mammary tumor cells and 
RNF8WT-reconstituted controls. Transcriptional upregulation of 
several NOTCH-target genes and components of the pathway were 
observed in RNF8-deficient cells (Figure 5G). Downregulation of 
a few Notch pathway elements was also observed (e.g., Numbl and 
Maml2; Figure 5G), perhaps reflecting the complex regulation of this 
signaling pathway and that, in addition to positive feedback, acti-
vation of Notch signaling also promotes negative feedback regula-
tion (5). Quantitative expression analyses performed on 3 different 
Rnf8–/– Trp53Δ/Δ mammary tumors reconstituted with either mock 
or RNF8WT confirmed the changes in expression of NOTCH-target 
genes associated with RNF8 deficiency (Figure 5H). These data 
reveal novel functions of RNF8 as a negative regulator of Notch sig-
naling in mouse mammary luminal progenitors and tumors.
RNF8 mediates negative regulation of Notch signaling in human 
breast cancer. To extend our studies of the effect of RNF8 on Notch 
signaling to relevant human breast cancer cells, we first performed 
quantitative expression analysis in RNF8-depleted breast cancer 
cell lines. Our data indicate a significant increase in the expression 
of NOTCH targets (HES1, HES2, HEY1, HEY2, and CCND1) in 
RNF8-depleted breast cancer cell lines compared with controls (Fig-
ure 6A and Supplemental Figure 4B). Consistent with these findings, 
overexpression of ectopic RNF8WT in the breast cancer cell line MDA-
MB-231 significantly reduced the protein level of N1ICD (Figure 6B), 
while CRISPR/Cas9–mediated knockout of RNF8 in MDA-MB-231 
and MCF7 cells led to increased protein expression of N1ICD and 
its downstream target HES1 (Figure 6C and Supplemental Figure 
4C). Further supporting the link between RNF8 and Notch signal-
ing in human breast cancer cells, analysis of data from The Cancer 
Genome Atlas (TCGA) revealed significant negative correlations 
between the expression of RNF8 and several NOTCH-target genes 
(HES1, HES2, HES5, HEY1, and CCND1), whereas positive correla-
tions were found with HDAC2, HIF1A, and NUMBL (Figure 6D).
To further assess the RNF8-NOTCH link and examine whether 
it is influenced by TP53 mutations, the TCGA data were analyzed 
CD24+CD61+) in Rnf8–/– females compared with WT littermates 
(Figure 4, D–F; P < 0.05, 56% ± 3.7% vs. 42% ± 1.6%), whereas the 
luminal differentiated (CD29loCD24+CD61–) and basal lineages 
(CD29hiCD24+) were found to be unaffected (Figure 4, D–F). Simi-
lar results were obtained using the marker CD49f instead of CD29 
(Supplemental Figure 3, B and C).
Next, we examined the clonal growth potential of Rnf8–/– 
MECs using a 3D colony-forming cell (CFC) assay (28). The num-
ber of CFCs was found to be double and the colonies were larger in 
size in Rnf8–/– relative to WT cell controls (Figure 4G and Supple-
mental Figure 3D). Moreover, Rnf8–/– mammary glands exhibited 
a 4-fold increase in the number of proliferating cells as indicated 
by Ki67 positivity (Figure 4H). Taken together, these data indicate 
that RNF8 deficiency promotes aberrant expansion of luminal 
progenitor cells in the mouse mammary epithelium.
Following on the previous observations and considering that 
TRP53 deficiency increased the risk of breast cancer in Rnf8–/– 
females, the expansion of luminal progenitors in Rnf8 and Trp53 
double-mutant background was also examined. Flow cytometry 
analyses of MECs were performed from inguinal mammary glands 
of 6.5-month-old WT, Rnf8–/–, WapCre Trp53fl/fl, and Rnf8–/– WapCre 
Trp53fl/fl females that had undergone 4 pregnancies and involutions, 
permitting complete deletion of Trp53‑floxed alleles in the luminal 
lineage (Supplemental Figure 3E). The expansion of the luminal lin-
eage associated with RNF8 deficiency persisted in 6.5-month-old 
females and was exacerbated by the additional deletion of Trp53 
(Figure 4I; Lin– luminal cells: WT, 34.8% ± 1.7%; Rnf8–/–, 45.5% ± 
1.5%; WapCre Trp53fl/fl, 31.5% ± 2.3%; and Rnf8–/– WapCre Trp53fl/fl, 
54.8% ± 2%; P < 0.05 Rnf8–/– vs. WT and Rnf8–/– vs. Rnf8–/– WapCre 
Trp53fl/fl; Supplemental Figure 3, F and G). Whole-mount staining 
of the axillary mammary glands from these 6.5-month-old females 
showed no sign of hyperplasia (Supplemental Figure 3H), preclud-
ing contribution of hyperplasia to the observed aberrant expansion 
of luminal progenitors in the absence of RNF8. These data unveil a 
novel function for RNF8 in the regulation of luminal lineage cell fate.
RNF8 negatively regulates Notch signaling in murine mammary 
luminal progenitors and tumors. On the basis of the aberrant expan-
sion of luminal progenitors in Rnf8-mutant females, we hypothe-
sized that RNF8 regulates signaling pathways required for epithe-
lial cell-fate determination. Therefore, we examined mammary 
cell subpopulations sorted from Rnf8–/– and WT females for expres-
sion of genes whose alterations are known to promote luminal 
expansion. Notably, the Notch signaling that plays important roles 
in the luminal cell-fate commitment (1, 29, 30) was found to be 
activated in Rnf8–/– luminal progenitors as indicated by the signifi-
cantly increased expression of the Notch-target genes Hes1, Hey1, 
Slug, and Ccnd1 (Figure 5A). The expression level of the prolifera-
tion marker Ccnd2 was also found to be increased in Rnf8–/– luminal 
progenitors, while expression of p18INK4c and FoxM1, factors involved 
in regulating mammary luminal cell fate (31, 32), remained unaf-
fected by RNF8 deficiency (Figure 5A). Next, given that interaction 
of NOTCH1 receptor with its ligands triggers its proteolytic cleav-
age and the release of its activated intracellular domain (N1ICD) 
(5), the effect of RNF8 deficiency on N1ICD expression level was 
analyzed in MECs. Rnf8–/– and Rnf8–/– Trp53Δ/Δ primary MECs were 
found to display elevated protein levels of N1ICD and its canoni-
cal target HES1 (Figure 5B and Supplemental Figure 4A). Overall, 
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for pathway associations using RNF8 coexpression ranks from all 
tumors or from those with somatic TP53 mutations. RNF8 expres-
sion was found to be negatively correlated with the Pathway Inter-
action Database (PID) NOTCH set in both settings (Supplemental 
Figure 4D). These data are consistent with the observed activa-
tion of Notch signaling in both RNF8-deficient MCF7 (TP53-WT) 
and MDA-MB-231 (TP53-mutant) breast cancer cell lines (Figure 
6C and Supplemental Figure 4C). Taken together, these results 
indicate that, as in murine mammary luminal progenitors and 
mammary tumors, RNF8 negatively regulates Notch signaling in 
human breast cancer.
RNF8 ubiquitylates N1ICD to control its turnover. To understand 
the molecular mechanisms underlying the observed negative reg-
ulation of Notch signaling, we first examined whether RNF8 inter-
acts with components of the corresponding pathway. N1ICD was 
detected in FLAG-tagged RNF8 immunoprecipitates from Rnf8–/– 
Trp53Δ/Δ mammary tumors reconstituted with RNF8-FLAG (Figure 
7A). Notably, no interaction was detected between RNF8 and RBPJ, 
a Notch transcriptional effector (2), and deficiency of RNF8 had no 
effect on RBPJ expression (Supplemental Figure 5A).
Ubiquitylation of N1ICD is critical for the regulation of its 
turnover (2). Examination of the expression of FBW7, an E3 ligase 
important for N1ICD ubiquitylation and degradation (2, 5), indi-
cated that it was unaffected by RNF8 deficiency (Supplemental 
Figure 5B). Next, we sought to determine whether RNF8 ubiqui-
tylates N1ICD. First, we performed an in vivo ubiquitylation assay 
and examined the effect of RNF8 deficiency on the ubiquityla-
tion of endogenous N1ICD. Immunoprecipitated N1ICD from 
RNF8-deficient mammary tumor cells reconstituted with RNF8-
FLAG, and left untreated or treated with the proteasome inhibitor 
MG132, migrated on SDS-PAGE gels as higher–molecular weight 
smears that were reactive to anti-ubiquitin (Ub) (Figure 7B). In 
contrast, these N1ICD Ub smears were greatly reduced in mock- 
reconstituted RNF8-deficient mammary tumor cells (Figure 7B). 
Next, we examined the effect of RNF8 on the ubiquitylation of the 
endogenous human N1ICD and observed that deficiency of RNF8 
in MDA-MB-231 cells remarkably decreased the ubiquitylation 
level of nuclear N1ICD (Figure 7C).
Ubiquitylation assays performed in HEK293T cells further 
supported RNF8-mediated polyubiquitylation of N1ICD, as co ex-
pression of exogenous RNF8 and Ub in these cells produced robust 
Ub smears of N1ICD compared with controls (Supplemental Fig-
ure 5C). Furthermore, examination of RNF8-catalyzed Ub link-
ages for N1ICD polyubiquitylation indicated that RNF8 mediates 
both K63 and K48 ubiquitylation of N1ICD (Supplemental Figure 
5C). Finally, in vitro ubiquitylation assays using recombinant pro-
teins (RNF8, N1ICD, E1, E2, and Ub) confirmed that N1ICD is a 
novel and direct ubiquitylation substrate for RNF8 (Figure 7D).
The importance of ubiquitylation in protein turnover (34, 
35) and the elevated N1ICD levels in RNF8-deficient mammary 
cells and tumors prompted us to perform cycloheximide chase 
experiments and examine the regulatory role of RNF8 on N1ICD. 
A strong reduction of the half-life of N1ICD was observed in 
RNF8-deficient mammary tumors upon their complementation 
with RNF8WT (Figure 7E).
RNF8 RING-finger and FHA domains are required for its 
function in DSB signaling (7–10). Therefore, we examined the 
contribution of these domains to RNF8-mediated negative regu-
lation of Notch signaling. Similarly to its inability to stimulate DSB 
signaling and repair (8), a catalytic dead form of RNF8 that car-
ries C406S substitution in the RING-finger domain (RNF8C406S) 
was defective in mediating N1ICD ubiquitylation and degradation 
(Figure 7, F and G). However, in contrast to the inability of the FHA 
mutant RNF8R42A to activate the repair cascade of DSBs (8, 9), this 
RNF8 mutant form effectively mediated N1ICD degradation (Fig-
ure 7G). These findings highlight the importance of the E3 ligase 
activity of RNF8 for N1ICD ubiquitylation and turnover, and indi-
cate that RNF8 negatively regulates Notch signaling in a manner 
independent of its recruitment to DSB sites.
Combined pharmacological inhibition of Notch signaling and 
PARP function promotes killing of RNF8‑deficient breast tumors. 
Based on the importance of RNF8 in Notch signaling and DSB 
repair, we examined whether impaired RNF8 function in breast 
cancer could be exploited therapeutically. First, exposure to dif-
ferent γ-secretase inhibitors (GSIs; RO4929097, YO-01027, 
and LY411575), which block Notch signaling, led to a significant 
growth impairment of Rnf8–/– Trp53Δ/Δ mammary tumor cells com-
pared with their RNF8WT-reconstituted controls (Figure 8, A and 
B). Consistent with the requirement of the FHA domain of RNF8 
for DSB repair (refs. 7–10 and Supplemental Figure 6A), but not for 
negative regulation of N1ICD (Figure 7G), Rnf8–/– Trp53Δ/Δ tumor 
cells reconstituted with the FHA mutant RNF8R42A displayed 
reduced sensitivity to GSI (Figure 8, A and B). In contrast, the E3 
ligase dead RNF8C406S, which exhibits defective ability to mediate 
DSB signaling/repair (ref. 8 and Supplemental Figure 6, A and B) 
together with impaired ubiquitylation and regulation of N1ICD 
(Figure 7, F and G), failed to rescue hypersensitivity of Rnf8–/– 
Trp53Δ/Δ tumor cells to GSI (Figure 8, A and B).
Defective DSB repair increases cancer radiosensitivity, while 
poly(ADP-ribose) polymerase inhibitors (PARPi) promote synthetic 
Figure 3. Deficiency of mouse RNF8 promotes genomic instability in MECs 
and mammary tumors. (A) Purified MECs from WT and Rnf8–/– littermate 
females at estrus phase were either left untreated (UT) or irradiated (5 Gy) 
and fixed at the indicated time points after IR. Cells were stained with anti-
γH2ax antibody and counterstained with DAPI. (B) Quantitative analysis 
of γH2AX subnuclear foci in WT and Rnf8–/– MECs from A. Cells with more 
than 3 foci were counted as foci-positive. Dot plots show mean ± SEM of 3 
independent experiments, and more than 100 cells for each condition and 
genotype were counted. (C) Representative images of spontaneous γH2AX 
subnuclear foci in Rnf8–/– Trp53Δ/Δ mammary tumor cells reconstituted with 
RNF8 or mock (empty vector). (D) Dot plots depicting quantification of 
the spontaneous subnuclear foci formation for γH2AX, 53BP1, BRCA1, and 
RAD51 observed in Rnf8–/– Trp53Δ/Δ mammary tumor cells reconstituted  
with RNF8 or mock. Three independent experiments were performed, and 
more than 100 cells were counted for each condition and genotype (mean 
± SEM). (E) Representative images of γH2AX, 53BP1, BRCA1, and RAD51 
subnuclear foci formation 6 hours after IR (5 Gy) of the indicated mammary 
tumor cells. (F) Dot plots depicting quantifications of subnuclear foci 
formation observed in E. Cells harboring at least 10 foci were counted as 
foci-positive. Three independent experiments were performed, and more 
than 100 cells were counted for each condition and genotype (mean ± 
SEM). (G and H) Dot plots depicting efficiencies of HR-mediated (G) and 
NHEJ-mediated (H) repair of I-SceI–induced DSBs in Rnf8 Trp53Δ/Δ mam-
mary tumor cells reconstituted as indicated (mean ± SEM). Three indepen-
dent experiments were performed. Two-sided Student’s t test: *P < 0.05, 
**P < 0.01, ***P < 0.001. Scale bars: 20 μm.
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Figure 4. Aberrant expansion of the luminal lineage in the mammary glands of Rnf8-mutant females. (A) Representative FACS plots showing Lin– 
(CD45–CD31–TER119–) luminal (L: CD29loCD24+) and basal (B: CD29hiCD24+) cells of inguinal mammary glands from 10- to 12-week-old WT and Rnf8–/– 
females. Data are representative of 3 independent experiments. (B) Dot plots depicting percentages of mammary luminal and basal populations from 
inguinal mammary glands from females in A (n = 3; mean ± SEM). (C) Dot plots depicting the absolute numbers of MECs and luminal and basal cells per 
inguinal mammary gland from WT and Rnf8–/– females (n = 3; mean ± SEM). (D) CD24+ MECs from A were analyzed for luminal progenitor (LP; CD29lo 
CD24+CD61+) and luminal differentiated (LD; CD29loCD24+CD61–) cells. Representative FACS images of 3 independent experiments are shown. (E and F) 
Dot plots depicting percentages (E) and absolute numbers (F) of LP and LD subpopulations from inguinal mammary glands of 10- to 12-week-old WT and 
Rnf8–/– females (n = 3; mean ± SEM). (G) Dot plots depicting the clonogenic potentials (mean ± SEM) in Matrigel of MECs from WT and Rnf8–/– littermate 
females (n = 4 each). (H) Representative images of 3 independent experiments showing Ki67/DAPI staining of mammary glands from 6.5-month-old WT 
and Rnf8–/– female littermates (scale bar: 100 μm), and dot plots depicting quantification of Ki67+ cells from mammary glands of WT and Rnf8–/– females 
(n = 3; mean ± SEM). A minimum of 1,000 cells per gland were counted. (I) Representative FACS plots showing luminal and basal cells of mammary glands 
from 6.5-month-old females as indicated (n = 4 each) that had undergone 4 pregnancies and involution to induce Cre-mediated deletion of Trp53. All 
females were at estrus phase. Two-sided Student’s t test: *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 5. RNF8 negatively regulates Notch signaling in murine mammary luminal progenitors and mammary tumors. (A) Quantitative reverse transcrip-
tase PCR (RT-qPCR) showing the expression changes of Notch targets and other genes in luminal progenitors from mammary glands of Rnf8–/– females at 
estrus phase compared with WT littermates. (B) Immunoblot analysis of N1ICD and HES1 in the indicated cells. (C) Representative immunohistochemical 
analysis of N1ICD levels in the indicated mammary adenocarcinomas (n = 3 each; scale bar: 25 μm). (D) Immunoblot showing expression of the indicated 
proteins in Rnf8–/– Trp53Δ/Δ mammary tumor cells reconstituted with mock or RNF8-FLAG. (E) RT-qPCR showing increased expression of indicated Notch1 
targets in mock-reconstituted, compared with RNF8WT-reconstituted, Rnf8–/– Trp53Δ/Δ mammary tumor cells engrafted for 40 days in NSG mice (see Figure 
1C). (F) Notch reporter 10xCBF1-Luc showing relative activation of Notch signaling in mock-reconstituted Rnf8–/– Trp53Δ/Δ mammary tumor cells compared 
with RNF8WT-reconstituted controls. *P < 0.05, ****P < 0.0001, 2-way ANOVA followed by Tukey’s test. (G) Heatmap showing the standardized expres-
sion of Notch targets and/or Notch pathway elements in Rnf8–/– Trp53Δ/Δ mammary tumor cells reconstituted with mock or RNF8-FLAG. (H) Notch targets 
differentially expressed in RNA-Seq analysis in G were validated by RT-qPCR in 3 different Rnf8–/– Trp53Δ/Δ mammary tumor cell lines and their RNF8- 
reconstituted controls. Data in B and D are representative of at least 3 experiments. A, E, F, and H: At least 3 experiments were performed, and the means 
± SEM are shown. A, E, and H: 2-sided Student’s t test, Rnf8–/– Trp53Δ/Δ mammary tumor cells mock-reconstituted compared with RNF8WT-reconstituted 
controls. *P < 0.05, **P < 0.01, ***P < 0.001. H: All P values were less than 0.05.
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naling, and similarly to mouse cell models, RNF8-deficient MCF7 
and MDA-MB-231 cells displayed increased sensitivity to GSI 
and PARPi (Figure 8, E–G). Importantly, both human cell mod-
els deficient for RNF8 (Figure 8, E–G), as well as Rnf8–/– Trp53Δ/Δ 
mouse mammary tumor cells (Figure 8, H and I), displayed higher 
sensitivity to the combination of GSI and PARPi compared with 
the respective controls. In summary, evidence from human and 
mouse breast cancer models highlights that combination of inhib-
itors of Notch signaling and PARP provides a precise therapeutic 
strategy for breast tumors with defective RNF8 function.
Discussion
Notch signaling and DSB signaling are fundamental cellular pro-
cesses, and their regulation is critical for minimizing breast cancer 
risks (2, 3, 23). Although these pathways are highly regulated, the 
lethality of cancer cells defective for HR-mediated repair (36). Con-
sidering the inherent defects of DSB signaling and HR-mediated 
repair associated with RNF8 deficiency (Figure 3), we examined the 
response of Rnf8–/– Trp53Δ/Δ mammary tumor cells, complemented 
with empty vector or RNF8WT, to IR and PARPi (KU0058948 and 
olaparib). In accordance with their impaired DSB repair and defec-
tive homologous recombination pathway, RNF8-deficient mam-
mary tumor cells were highly sensitive to both IR and PARPi com-
pared with their control counterparts (Figure 8, C and D).
Next, the above therapeutic opportunity was assessed in 
human breast cancer cells. Examination of RNF8-deficient MDA-
MB-231 and MCF7 breast cancer cells showed impaired DSB 
repair as indicated by accumulation of unresolved γH2AX foci 24 
hours after IR (Supplemental Figure 6, C–E). Consistent with their 
impaired repair of DSBs and increased activation of Notch1 sig-
Figure 6. RNF8 mediates negative regulation of Notch signaling in human breast cancer. (A) RT-qPCR analysis of the fold change in the expression of 
Notch targets in the indicated RNF8-knockdown (shRNF8) human breast cancer cell lines compared with their controls (shCtr). Dot plots show mean ± 
SEM of 3 independent experiments. *P < 0.05, ***P < 0.001, ****P < 0.0001, 1-way ANOVA followed by Tukey’s test. (B) Immunoblot analysis of the indi-
cated proteins in MDA-MB-231 cells transfected with FLAG empty vector (–) or RNF8-FLAG. (C) Immunoblot analysis of cytoplasmic (CE) and nuclear (NE) 
extracts from indicated cells. (D) Supervised clustering (from low to high RNF8 expression) of the profiles of genes with a significant negative or positive 
correlation (Pearson’s correlation coefficients [PCCs]) with RNF8 in the TCGA breast cancer (BRCA) data set. The breast cancer subtypes based on PAM50 
are indicated. Data in B and C are representative of at least 3 experiments.
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Figure 7. RNF8 polyubiquitylates N1ICD to promote its turnover. (A) N1ICD interacts with RNF8. Immunoblot (IB) analysis of N1ICD and RNF8-FLAG fol-
lowing anti-FLAG immunoprecipitation (IP) from RNF8-deficient mammary tumor cells and their RNF8-restored isogenic controls. WCL, whole cell lysate. 
(B) Ubiquitylation of N1ICD depends on RNF8 in vivo. RNF8-deficient mammary tumor cells complemented with empty FLAG vector (–) or RNF8-FLAG (+) 
were either left untreated or treated with the proteasome inhibitor MG132 and subjected to IP with anti-N1ICD. Immunoblot analysis was performed with 
the indicated antibodies. (C) Ubiquitylation of endogenous N1ICD by RNF8. Nuclear (NE) and cytoplasmic (CE) extracts prepared from MDA-MB-231 cells 
deleted of RNF8 (sgRNF8) and their controls (sgCh10) were subjected to IP with anti-N1ICD or IgG, followed by immunoblot as indicated. (D) In vitro ubiq-
uitylation of recombinant N1ICD in the presence of recombinant RNF8, UBE1 (E1), Ubc13 (E2), and Ub proteins. (E) Cycloheximide (CHX) chase analysis 
of N1ICD protein half-lives in RNF8-deficient mammary tumor cells and their RNF8-restored isogenic controls. Cells were incubated in the presence of CHX 
for the indicated times, and immunoblots were performed using the indicated antibodies. N1ICD levels were quantified by densitometry using ImageJ and 
normalized with β-actin level. N1ICD fold decrease is indicated. (F) Requirement of RNF8 catalytic activity for N1ICD ubiquitylation. HEK293T cells, trans-
fected with empty FLAG vector (–), RNF8WT-FLAG, RNF8C406S-FLAG (catalytically inactive), and Ub-HA as indicated, were subjected to IP with anti-N1ICD 
followed by immunoblot for HA and N1ICD. WCL was analyzed by immunoblot as indicated. (G) FHA domain of RNF8, responsible for its recruitment to 
DSB sites, is dispensable for N1ICD turnover. Immunoblots showing expression of N1ICD and RNF8-FLAG in RNF8-deficient mammary tumor cells recon-
stituted with FLAG-RNF8WT, FLAG-RNF8C406S, FLAG-RNF8R42A (FHA domain mutant), or empty FLAG vector (–) as indicated. Data in A–G are representative 
of at least 3 experiments.
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Figure 8. RNF8-deficient breast tumors are sensitive to combination of pharmacological inhibitors of Notch signaling and PARP. (A) Representative dish 
images of 3 independent experiments in triplicate showing clonogenic survival under GSI (RO4929097) treatments of Rnf8–/– Trp53Δ/Δ mammary tumor cells recon-
stituted with mock or either WT or mutant forms of RNF8 as indicated. Cells were fixed and stained with crystal violet at day 12 of culture. (B) Dot plots depicting 
percentages of clonogenic survival of Rnf8–/– Trp53Δ/Δ mammary tumor cells and their reconstituted controls (as indicated) after 12 days of treatment with different 
GSIs (RO, RO4929097; YO, YO-01027; LY, LY411575). (C and D) Dot plots depicting clonogenic survival of Rnf8–/– Trp53Δ/Δ mammary tumor cells, reconstituted 
with mock or RNF8, 12 days after IR (C) or treatment with the PARPi KU0058948 (D). (E) Representative dish images showing clonogenic survival of MCF7 cells 
deficient for RNF8 (sgRNF8) and their controls (sgCh10) 25 days after treatment with GSI (RO4929097), PARPi (olaparib), or their combination as indicated. Images 
are representative of 3 independent experiments in triplicate. (F and G) Dot plots depicting percentages of clonogenic survival of MCF7 cells (F) and MDA-MB-231 
cells (G) deficient for RNF8 (sgRNF8) and their controls (sgCh10) after treatment with GSI (RO4929097), PARPi (olaparib), or their combination as indicated. (H) 
Representative images of clonogenic survival of the indicated mammary tumor cells 12 days after treatment with GSI (RO4929097), PARPi (olaparib), or their 
combination as indicated. (I) Dot plots depicting clonogenic survival of Rnf8–/– Trp53Δ/Δ mammary tumor cells reconstituted with mock or RNF8 after treatment (12 
days) with GSI (RO4929097), PARPi (olaparib), or their combination as indicated. B–D, F, G, and I: n = 3; mean ± SEM, normalized to DMSO-treated controls except 
for C, in which normalization was to nonirradiated controls. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, 2-way ANOVA followed by Tukey’s test.
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dispensable for RNF8-mediated downregulation of Notch signal-
ing. Therefore, despite coregulation of Notch signaling and DSB 
repair, recruitment of RNF8 to chromatin at DSBs, or its possible 
binding to phosphorylated proteins through its FHA domain, is not 
required for ubiquitylation of N1ICD. Therefore, the initial mech-
anisms by which RNF8 engages its regulation of Notch1 signaling 
and DSB repair cascade appear to be different.
Combination therapy offers the advantage of targeting differ-
ent molecular processes to enhance tumor cell death and reduce 
the risk of cancer recurrence. The simultaneous alteration of Notch 
signaling and DSB repair associated with defective RNF8 expres-
sion in breast cancer provides a unique therapeutic opportunity 
using specific inhibitors of Notch and PARP. Indeed, we observed 
increased sensitivity of mouse and human breast cancer cells defi-
cient for RNF8 to individual treatment with GSI or PARPi. Notably, 
this sensitivity of RNF8-deficient breast cancer cells was further 
increased in response to combination of pharmacological inhibi-
tors of Notch signaling and PARP.
In summary, our data uncover an unanticipated role for RNF8 
in the regulation of cell-fate determination of mammary luminal 
progenitors and demonstrate a novel function for RNF8 in the 
regulation of Notch1 signaling through the control of N1ICD turn-
over. We also provide evidence that RNF8 deficiency increases the 
risk of mammary tumorigenesis. Thus, while RNF8 is an integral 
component of DSB signaling and, as such, its deficiency or loss 
of function can potentially contribute to increased breast cancer 
risk, we propose that the novel role of RNF8 in fine-tuning Notch1 
signaling is not only important for cell-fate determination of lumi-
nal progenitors, but also contributes to protection from breast 
cancer development (Figure 9). The high efficacy of combination 
treatment of RNF8-deficient breast tumors with GSI and PARPi 
suggests that such combination may have therapeutic benefit for 
patients with defective expression or function of RNF8. Elucida-
tion of the mechanisms that modulate RNF8’s negative regulation 
of Notch1 signaling and its impact on the fate and transformation 
of MECs sheds new light on the mechanisms of breast cancer 
development and uncovers a novel avenue for targeted therapy.
Methods
Mice. Rnf8–/– mice (AS0574 strain) were previously reported (11). 
Trp53fl/fl conditional mutant mice (37) (NCI Mouse Repository) were 
intercrossed with WapCre transgenic mice (The Jackson Laboratory) to 
obtain WapCre Trp53fl/fl mice. Subsequent crosses of Rnf8–/– mice with 
WapCre Trp53fl/fl mice generated Rnf8–/– WapCre Trp53fl/fl females. Mice 
in this study were on a mixed 129/J × C57BL/6 genetic background and 
were genotyped by PCR for Rnf8WT (forward 5′-TGATGACACCTGGG-
CATGT-3′; reverse 5′-TCTTTGAGACAGCGCCTGG-3′), Rnf8 mutant 
(forward 5′-TCAAAGGTTTGCCCTCTGAT-3′; reverse 5′-CGGAG-
CGGATCTCAAACTCT-3′), Trp53fl (forward 5′-CAGCCTCT-
GTTCCACATACACT-3′; common 5′-TGGATGGTGGTATACTCA-
GAGC-3′), Trp53WT (forward 5′-AGGCTTAGAGGTGCAAGCTG-3′; 
common 5′-TGGATGGTGGTATACTCAGAGC-3′), and Cre (forward 
5′-CCATCTGCCACCAGCCAG-3′; reverse 5′-TCGCCATCTTCCAG-
CAGG-3′). All mice were housed in a pathogen-free mouse facility 
at the Princess Margaret Cancer Centre. Ten- to 12-week-old female 
mice were used for experiments, unless indicated otherwise in the 
figure legends. To rule out the effect of hormonal changes on MECs 
mechanisms that may mediate their coregulation remain poorly 
understood. This work reveals that RNF8 mediates this coregula-
tion of Notch and DSB signaling in the mammary epithelium and, 
if perturbed, promotes breast cancer (Figure 9).
Notch signaling is essential for luminal cell-fate determina-
tion in the mammary epithelium (1, 29). Constitutive activation 
of Notch signaling in mammary luminal progenitors promotes 
the expansion of these progenitors and increases the risk for their 
malignant transformation (1, 29, 30). In this study, we demonstrate 
that RNF8 is a potent negative regulator of Notch signaling and its 
deficiency in MECs causes sustained activation of this signaling, 
likely contributing to the aberrant expansion of mammary lumi-
nal progenitors. Our study reveals that RNF8 negatively regulates 
the Notch1 signaling pathway through its ubiquitylation of N1ICD, 
and its subsequent targeting for degradation. By restraining intra-
cellular levels of N1ICD, RNF8 restrains transcriptional activity of 
NOTCH-target genes to promote tissue homeostasis. Consistent 
with the elevated levels of N1ICD and activation of Notch signal-
ing in mammary epithelium of Rnf8‑mutant female mice, human 
breast cancer cell lines deficient for RNF8 also displayed elevated 
levels of N1ICD and Notch signaling. Gene expression profile 
analyses using TCGA breast cancer data support the link between 
low RNF8 expression and abnormal Notch signaling.
The existence of several RNF8 isoforms prompted us to 
examine whether a correlation exists between breast cancer 
relapse–free survival and the expression level of the full-length 
isoform that encodes for functional RNF8. These analyses 
revealed that low expression of the full-length RNF8 isoform that 
contains both its FHA and RING-finger domains correlates with 
poor prognosis for breast cancer patients. These data suggest a 
prognostic role for the integral function of RNF8 in breast can-
cer. This link may be independent of an impact on breast cancer 
initiation; however, our results examining female mice carrying 
mutation of Rnf8 indicate that loss of RNF8 increases the risk of 
mammary tumorigenesis. Nonetheless, studies in different can-
cer settings may be warranted to further decipher the proposed 
dual impact of RNF8 on breast cancer.
Given the novel role of RNF8 as a negative regulator of Notch 
signaling, we hypothesized that when RNF8 is absent or nonfunc-
tional, sustained Notch1 signaling drives aberrant proliferation of 
luminal progenitor cells. This aberrant proliferation, in conjunc-
tion with increased genomic instability, in the absence of RNF8 
results in spontaneous mammary tumorigenesis. Consistent with 
elevated levels of DSBs and TRP53 activation in RNF8-deficient 
MECs, the risk of spontaneous mammary tumorigenesis in Rnf8–/– 
females was further increased in the presence of homozygous 
or heterozygous Trp53 mutations in mammary epithelium. Our 
observation that tumors isolated from Rnf8–/– Trp53Δ/WT mice often 
displayed a loss of heterozygosity for Trp53 suggests that activated 
TRP53 plays a critical role in the suppression of RNF8-associated 
mammary tumorigenesis.
The RING-finger domain of RNF8 is critical for its E3 ligase 
function and for the positive regulation of DSB signaling cas-
cade (7–10). Our study demonstrates that the RNF8 RING-finger 
domain is also essential to mediate negative regulation of Notch1 
signaling. In contrast, the phosphothreonine-binding FHA domain 
of RNF8 responsible for recruitment of RNF8 to DSB sites (7–10) is 
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opaque 96-well tissue culture plates (Greiner CellStar). Luciferase 
activities of the transfected cells were measured using the Dual Glo 
Luciferase assay kit (Promega) with firefly luciferase–based reporter 
gene activity normalized to the Renilla luciferase internal control 
reporter activity. Background autoluminescence from nontransfected 
cells was subtracted from the autoluminescence of the transfected cells.
Transfection and virus transduction. HEK293T cells (ATCC) and 
the human breast cancer cell line MDA-MB-231 (ATCC) were trans-
fected using PolyJet DNA in vitro transfection reagent (SignaGen Lab-
oratories). Mouse mammary tumors were processed into single-cell 
suspensions following the same procedure for mammary gland single- 
cell suspension described above. Then, mammary tumor cells were 
analyzed by flow cytometry for Lin– expression of CD49f, CD24, and 
CD61, and were cultured in vitro into stable cell lines and validated by 
Western blot, PCR, and Southern blot for their respective mutations. 
All tumor cells were cultured in DMEM supplemented with 10% FBS, 
5 × 10–5 M 2-ME, 100 U/ml penicillin, and 100 μg/ml streptomycin 
(complete DMEM), and were maintained in a humidified atmosphere 
at 37°C and 5% CO2. To complement Rnf8
–/– Trp53Δ/Δ mammary tumor 
cell lines with WT and mutant forms of RNF8, cDNA for mouse Rnf8 
(WT, C406S, and R42A) was subcloned into MSCV-FLAG. Rnf8 
retroviral constructs and empty MSCV-FLAG were transfected to 
Phoenix cells, and virus supernatants were collected 48 and 72 hours 
after transfection. Three independent mammary tumor cell lines were 
transduced with the harvested retroviral supernatants in the presence 
of Polybrene, and selected for puromycin resistance. Human breast 
cancer cell lines MDA-MB-231, MDA-MB-468, and T47D (ATCC) 
were transduced with PLKO-puro lentiviruses encoding shRNAs tar-
geting human RNF8 (shRNA#1: TRCN0000003438, 5′-TGGAG-
CAACTAGAGAAGACTT-3′; and shRNA#2: TRCN0000003441, 
5′-CCAAAGAATGACCAAATGATA-3′). As control, cells were trans-
duced with lentiviral particles carrying the empty pLKO.1-puro vector 
(Addgene, 8453). The expression of RNF8 was examined by Western 
(26, 27), all experimental females were followed to determine their 
phases of estrus cycle for at least 4 continuous days. Females at the 
estrus cycle were used for all experiments. Survival cohorts of female 
mice were monitored for mammary tumor onset by palpation as 
well as signs of other tumors twice a week for over 600 days. Power 
analysis was performed to determine the minimum number of ani-
mals needed to have a statistical power of 80% for comparing Rnf8–/– 
WapCre Trp53fl/fl and WapCre Trp53fl/fl survival analysis. Log-rank test 
was used for statistical analysis of survival curves, and was performed 
using OriginLab Pro 8 software. For all animal experiments, only 
females were included, and block randomization was used to warrant a 
balance in sample size across the different genotypes. We did not 
exclude any animals from the experiments. Investigators were not 
blinded to the genotype identity of mice.
Southern blot analysis for loss of heterozygosity. Genomic DNA from 
Rnf8–/– WapCre Trp53fl/WT mammary tumors and respective tails of the 
tumor-bearing females was digested with BglII followed by blotting 
and hybridization using standard procedures.
PCR analysis of WapCre‑mediated Trp53 deletion. Genomic DNA 
was isolated from cell-sorted Lin– mammary epithelial subpopulations 
(CD49floCD24+CD61– luminal differentiated cells; CD49floCD24+CD61+ 
luminal progenitor cells; CD49fhiCD24+ basal cells) of WapCre Trp53fl/fl 
females at estrus phase that had undergone zero pregnancies (16 weeks 
old), 2 pregnancies (4 months old), and 4 pregnancies (6.5 months old) 
and involution. Touchdown PCR was performed on equal amounts of 
genomic DNA to detect the presence of Trp53WT, Trp53fl, and Trp53Δ2–10 
alleles as previously described (37).
Notch reporter assay. RNF8-deficient mammary tumor cells (pas-
sage 5) and their respective isogenic cells reconstituted with RNF8 were 
cotransfected with the reporter construct 10xCBF1-Luc (33) and Renilla 
luciferase using PolyJet DNA in vitro transfection reagent (SignaGen 
Laboratories). Forty-eight hours later, transfected cells were counted 
and plated at 2.5 × 105 cells per 75 μl DMEM per well of flat-bottomed 
Figure 9. A schematic diagram depicting a 
model for RNF8-mediated coregulation of Notch 
signaling and DSB repair and the breast cancer–
suppressive function of RNF8. RNF8 is recruited 
to DSBs, where it ubiquitylates histones at the 
flanking DNA damage sites. This ubiquitylation 
triggers recruitment of downstream DSB signaling 
and repair proteins (e.g., RNF168 and BRCA1) to 
DNA damage sites, allowing their repair. Loss of 
RNF8 expression or function impairs DSB repair, 
leading to genomic instability and increased breast 
cancer risk. Our data reveal an important role for 
RNF8 in mediating negative regulation of Notch 
signaling. RNF8 ubiquitylates the active form of 
NOTCH1 (N1ICD) to promote its turnover. Thus, 
impaired RNF8 expression or function results in 
constitutive activation of Notch signaling in mam-
mary luminal progenitors, a process that promotes 
expansion of these progenitors and increases their 
risk for malignant transformation. We propose 
that RNF8 coregulation of Notch signaling and 
DSB repair is critical for its suppressor function in 
breast cancer. Small filled circles indicate γH2ax 
(black); phosphorylation (gray); and Ub (red).
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mammary glands of 10- to 12-week-old females at estrus phase. Five 
thousand total mammary cells were seeded into 50 μl of growth factor– 
reduced Matrigel (BD Biosciences) and cultured as a droplet on the 
center of 6-cm dishes containing mouse EpiCult-B medium supple-
mented with 5% FBS, cytokines EGF and FGF, and EpiCult-B pro-
liferation supplements (STEMCELL Technologies) as previously 
described (26). Colonies were blindly scored after 12 days of cul-
ture under a light microscope, and tiled image composites spanning 
Matrigel droplets were then taken.
In vivo growth of Rnf8‑deficient mammary tumor cells in NSG 
mice. Logarithmically growing Rnf8–/– WapCre Trp53fl/fl tumor cells 
and their RNF8-complemented counterparts were harvested, resus-
pended in PBS, and combined in a 1:1 ratio with Matrigel (Corning) 
at a concentration of 1.0 × 107 cells/ml. One hundred microliters of 
tumor cell suspensions were orthotopically injected into the inguinal 
fat pads of female NSG mice (6–7 weeks old; The Jackson Laborato-
ry). Tumor volume was measured externally using a digital caliper. 
Tumor volume = (π × length × width2)/6, where length represents the 
largest tumor diameter and width represents the diameter perpen-
dicular to the length.
Histological analysis and immunohistochemistry. Paraffin sections 
of mammary glands and mammary tumors were stained with H&E 
for histological analysis as previously described (11). For immuno-
histochemistry, tissues and tumor sections were prepared according to 
standard protocols (11). Antibodies used were anti-CK18 (10R-10302; 
Fitzgerald), anti-CK14 (PRB-155P; Covance), anti-Ki67 (NB500-
170; Novus Biologicals), and anti-N1ICD (4147, Val1744 [D3B8]; Cell 
Signaling Technology). The investigators were blinded during the 
scoring of Ki67+ cells.
Immunofluorescence. Staining for subnuclear foci formation was 
performed as previously described (11). MECs from females at estrus 
phase were purified by negative depletion using magnetic beads 
(Dynabeads; Invitrogen). FACS analysis indicated that the purity 
of the isolated MECs was greater than 97%. Immunofluorescence 
staining for subnuclear foci was also performed on RNF8-deficient 
mammary tumors and human breast cancer cell lines MDA-MB-231 
and MCF7. Primary antibodies used for immunofluorescence stain-
ing were anti-γH2AX (07-164, Millipore; 05-636 JBW301, Millipore), 
anti-53BP1 (A300-272; Bethyl), anti-RAD51 (sc-8349, clone H-92; 
Santa Cruz Biotechnology), and anti-BRCA1 (39) (homemade, raised 
against aa 831–845 of murine BRCA1). Anti-rabbit or anti-mouse IgG 
conjugated with Alexa Fluor 488 or 594 (Invitrogen, catalog A11008, 
A11037, A11059, A11032) was used for secondary staining. Sub-
sequently, slides were counterstained with DAPI (Invitrogen) and 
mounted with Mowiol (Sigma-Aldrich). Images were taken using a 
fluorescence microscope (Leica) under ×100 magnifications. ImageJ 
software (NIH) was used to process the raw data. The investigators 
were blinded during the scoring of foci-positive cells.
Clonogenic survival assay. Exponentially growing mouse mammary 
and human breast tumor cells were seeded at 200 cells per 6-cm dish 
in complete DMEM. Tumor cells were either left untreated, cultured 
in the presence of 0.1–5 μM of PARP inhibitor (KU0058948, Axon 
Medchem; or olaparib, Selleckchem), or subjected to γ-irradiation (2–8 
Gy). For Notch inhibitor treatment, mammary tumor cells were either 
left untreated or treated with γ-secretase inhibitors (RO4929097, 
1–10 μM; LY411575, 5 μM; YO-01027, 5 μM; Selleckchem). Olaparib (2 
μM) and RO4929097 (10 μM) were used for combination treatments. 
blotting. Human breast cancer cell lines MDA-MB-231 and MCF7 
(ATCC) were also transduced with lentiCRISPR v2 (Addgene, 52961) 
lentiviruses encoding short-guide RNAs (sgRNAs) targeting human 
RNF8 (sgRNF8.1: 5′-CGGGGTCGAGTAGGCGATGG-3′; sgRNF8.2: 
5′-CCATCGCCTACTCGACCCCG-3′) or a control lentiCRISPR v2 
vector loaded with a sgRNA targeting a noncoding region of chromo-
some 10 (sgCh10: 5′-CAATACACCCATAGTTGAGC-3′). All cell lines 
were tested to be mycoplasma-free.
DSB repair assays. To determine HR and NHEJ efficiency, HR 
and NHEJ reporter constructs (38) were linearized with the I-SceI 
restriction enzyme and transfected to mammary tumor cell lines 
using GenJet in vitro DNA transfection kit (SignaGen Laboratories). 
RFP construct was cotransfected as internal control. Transfected cells 
were examined 48 hours later by flow cytometry for their expression 
of eGFP and RFP. Repair efficiencies of HR and NHEJ were expressed 
as eGFP+/RFP+ ratios.
Flow cytometry analysis and sorting of MECs. Mammary glands 
from female mice at estrus phase were processed into mouse EpiCult-B 
medium supplemented with 3% FBS (Wisent), 750 U/ml collagenase, 
and 250 U/ml hyaluronidase, and incubated at 37°C for 2.5 hours. Sub-
sequently, mammary organoids were subjected to red blood cell lysis 
in NH4Cl, followed by further dissociation in 0.25% trypsin for 2 min-
utes, and then in a mixture of 5 mg/ml dispase and 0.1 mg/ml DNase I 
for 2 minutes. After filtering through a 40-μm mesh, mammary single- 
cell suspensions were obtained. All the reagents described above 
were from STEMCELL Technologies, and all antibodies described 
below were from Thermo Fisher Scientific unless otherwise indicated. 
Mammary cell suspensions were blocked with Fc receptor antibody, 
followed by incubation with biotinylated anti-CD31 (14-0311), anti-
CD45 (13-0451; clone 30-F11), and anti-TER119 (13-5921). CD45+ 
immune cells, TER119+ red blood cells, and CD31+ endothelial cells 
were further conjugated with streptavidin-PE-Cy7 (25-4317) and were 
excluded using flow cytometry. Propidium iodide (Sigma-Aldrich) 
was used to stain dead cells, which were excluded from analysis. MEC 
subpopulations were identified using anti-CD49f–FITC (11-0495; 
clone GoH3), anti-CD24–PE (12-0242; clone M1/69), anti-CD29–
FITC (11-0291; clone ebioHMb1-1), and anti-CD61–APC (MCD6105; 
Invitrogen) using a FACSCalibur (BD Biosciences) or Canto (BD Bio-
sciences) and analyzed using FlowJo software (Tree Star Inc.). Cell 
sorting of mammary epithelial subpopulations was performed on a 
FACSAria (BD Biosciences), and the purity of sorted populations was 
routinely greater than 97%.
Whole‑mount staining. Mammary glands from females were 
mounted on glass slides and fixed with Carnoy’s formula 2 fixative 
(10% glacial acetic acid, 30% chloroform, and 60% absolute etha-
nol) for 12 hours. Fixed mammary glands were processed through a 
hydration series using descending concentrations of ethanol (70%, 
50%, and 20%; 15 minutes each) and distilled water for 10 minutes, 
followed by staining in a carmine-alum mix (0.2% carmine [Sigma- 
Aldrich] and 0.5% aluminum potassium sulfate [Sigma-Aldrich]) for 
16 hours. Subsequently, the stained mammary glands were de hy-
drated through ascending concentrations of ethanol (25%, 50%, 
70%, and 100%; 15 minutes each) and cleared in xylene overnight, 
and then the stained mammary glands were mounted with Permount 
medium (Fisher Scientific).
3D Matrigel mammary colony‑forming assay. Mammary single- 
cell suspensions were prepared as described above from inguinal 
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masked for low-complexity or low-quality sequence, and subsequently 
mapped to the mouse genome (build mm10, GRCm38) using STAR 
(version 2.4.0f1) (40). The SAM/BAM files were further processed 
using SAMtools (version 0.1.18) (41), and read count quantitation was 
obtained using BEDTools multicov (version 2.25.0) (42). Normaliza-
tion of read counts and differential expression analysis between geno-
types were carried out using the DESeq2 R package in Bioconductor 
(release 2.13). The Notch signaling pathway annotation was obtained 
from WikiPathways (43).
In vivo ubiquitylation assay. Rnf8–/– mammary tumor cells com-
plemented with empty FLAG vector or RNF8-FLAG were either left 
untreated or treated with the proteasome inhibitor MG132 (20 μM; 
Selleckchem) for 6 hours, and ubiquitylation levels of N1ICD were 
examined as previously described (44). In vivo ubiquitylation of 
N1ICD in MDA-MB-231 cells deleted of endogenous RNF8, and their 
controls, was similarly examined.
Ubiquitylation assay. HEK293T cells were transfected with 
Rnf8WT‑FLAG or Rnf8C406S‑FLAG, and constructs encoding Ub-WT 
(Addgene, pRK5-HA-Ub‑WT [ID 17608]) or mutated Ub-HA (pRK5‑
HA-Ub‑K48 [ID 17605], pRK5-HA-Ub‑K63 [ID 17606]) as indicated. 
Forty-eight hours later, cell lysates were prepared, precleared with 
Protein A-Sepharose beads (Life Technologies), and subjected to 
immunoprecipitation using anti-N1ICD (Cell Signaling Technology). 
Subsequently, the beads were washed, and proteins released from the 
beads by boiling in 2× SDS-PAGE sample buffer. Immunoblot analysis 
was performed using the indicated antibodies.
In vitro ubiquitylation assay. Recombinant RNF8 (45) was a gift 
from T.K. Sixma (Division of Biochemistry and Cancer Genomics 
Centre, Netherlands Cancer Institute, Amsterdam, the Nether-
lands). UBE1, Ubc13, and Ub recombinant proteins were gifts from 
C. Arrowsmith (Princess Margaret Cancer Centre, University Health 
Network and Department of Medical Biophysics, University of Toron-
to, Toronto, Ontario, Canada). Recombinant N1ICD (2 μg; Addgene, 
47612), recombinant RNF8 (1 μg), UBE1 (0.1 μg; E1), Ubc13 (0.2 μg; 
E2), Ub (5 μg), and ATP (5 mM) were mixed, and the reactions were 
incubated at 30°C for 2 hours in buffer containing 50 mM Tris/HCl 
(pH 7.5), 5 mM MgCl2, and 1 mM DTT and examined by immunoblot 
as previously reported (39).
Cycloheximide chase analysis. Rnf8–/– Trp53Δ/Δ mammary tumor 
cells reconstituted with empty vector (mock) or RNF8 were seeded 
onto 6-cm dishes overnight. Cells were then either left untreated or 
treated with 150 μM of cycloheximide for 0.5–6 hours, and immuno-
blot analysis was performed to determine levels of N1ICD, RNF8-
FLAG, and β-actin.
Bioinformatics. To characterize clinical relevance of RNF8 in 
human breast cancer, we used KM Plotter (http://kmplot.com) (19), 
2017 version, with data from 5,142 breast cancer samples, of which 
3,955 had patient survival information, downloaded from GEO (Affy-
metrix microarrays only), the European Genome-Phenome Archive 
(EGA), and TCGA. We plotted relapse-free survival using the median 
expression level of RNF8 (probes 203160_s_at and 203161_s_at) to clas-
sify breast cancer cases as having either high or low RNF8 expression. 
The specificity of the 2 RNF8 probes available in the KM Plotter was 
analyzed using Ensembl (www.ensembl.org). Isoforms of RNF8 were 
inspected using Ensembl and UniProt (http://www.uniprot.org).
Statistics. Two-tailed unpaired Student’s t test was used to com-
pare 2 means. Multiple comparisons were performed using 1-way 
Medium was changed every 4 days to replenish drug levels. Cells were 
allowed to grow for 12–25 days, depending on the tumor cells, before 
their fixation with methanol and staining with crystal violet. Numbers 
of colonies in each dish were counted, and pictures of the dishes were 
taken. All experiments were performed in triplicate. Data from treated 
samples were normalized to their respective untreated controls. The 
investigators were blinded during the scoring of colonies.
Protein analysis and cytoplasmic and nuclear extract preparation. 
Immunoblot analyses were performed using standard protocols. For 
fractionation, 3 × 107 cells were washed with PBS and resuspended 
in 200 μl of buffer A (10 mM HEPES [pH 7.9], 50 mM NaCl, 0.5 M 
sucrose, 0.1 mM EDTA, 1 mM DTT, 0.5% Triton-X and protease inhib-
itor mixture [Roche Molecular Biochemicals]). The cells were incu-
bated for 5 minutes on ice, and subsequently nuclei were collected 
in the pellet (P1) by low-speed centrifugation (1,000 g, 10 minutes, 
4°C) and the supernatant collected as cytoplasmic extract. The pellet 
was washed once with buffer A; then nuclear extracts were pre-
pared by addition of 200 μl of buffer B (10 mM HEPES [pH 7.9], 
250 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 0.1% NP40 and prote-
ase inhibitor mixture), followed by 10 minutes of incubation on ice 
and subsequent solubilization using sonication. Antibodies used 
for immunoblotting were against N1ICD (Val1744; Cell Signaling 
Technology, 4147), HES1 (sc-25392, clone H-140; Santa Cruz Bio-
technology), CCND1 (sc-717, clone C-20; Santa Cruz Biotechnol-
ogy), TRP53 (sc-6243, clone FL393; Santa Cruz Biotechnology), 
P21 (sc-471, clone M19; Santa Cruz Biotechnology), BAX (sc-493, 
clone N-20; Santa Cruz Biotechnology), FLAG (F1804, clone M2; 
Sigma-Aldrich), HA (11583816001, clone 12CA5; Sigma-Aldrich), 
ubiquitin (NB300-130, clone Ubi-1; Novus Biologicals), RNF8 
(sc-271462, clone B-2, Santa Cruz Biotechnology; and NB100-1176, 
Novus Biologicals), lamin B (sc-3739; Santa Cruz Biotechnology), 
α-tubulin (sc-53646; Santa Cruz Biotechnology), RBPJ (5442; Cell 
Signaling Technology), FBW7 (40-1500; Invitrogen), and β-actin 
(sc-47778, clone C4; Santa Cruz Biotechnology).
Quantitative reverse transcription PCR. Total RNA from FACS-sorted 
primary mammary cell subpopulations, mammary tumors, and human 
breast cancer cell lines was extracted using Trizol (Invitrogen). RNA sam-
ples were treated with an RNase-free DNA digestion kit (Invitrogen), and 
were reverse transcribed into cDNA using the oligo-dT priming method 
of the First-Strand cDNA synthesis system kit (Invitrogen). Quantitative 
reverse transcriptase PCR (RT-qPCR) was performed using SYBR Green 
PCR Master Mix (Applied Biosystems) and the gene-specific primers as 
indicated in Supplemental Table 1. Assays were performed in triplicate 
using ABI PRISM 7900HT Sequence Detection System (Applied Bio-
systems), followed by data analysis using Sequence Detection System 
software version 2.1 (Applied Biosystems). The expression level of each 
target gene was normalized to either human or mouse endogenous 
β‑actin and GAPDH transcripts.
RNA sequencing analysis. Total RNA from mammary tumor cell 
lines was extracted using the RNeasy kit (Qiagen), and RNA quality 
was assessed by Agilent 2100 Bioanalyzer (Agilent Technologies). 
Illumina TruSeq Stranded mRNA Libraries for RNA-Seq were pre-
pared according to Illumina TruSeq protocols. Samples were then 
sequenced on an Illumina HiSeq (100-bp paired-end). The RNA-Seq 
data have been deposited to the Gene Expression Omnibus (GEO; 
reference GSE76075; https://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE76075). The RNA-Seq reads were trimmed for adaptors, 
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